Latest news with #Candida
Indian Express
a day ago
- Health
- Indian Express
Wellness expert warns your morning bread can be ‘the most dangerous thing you put in body'; learn more about the ‘auto-brewery syndrome'
For many, bread is a breakfast staple, but wellness expert Dr Mickey Mehta has raised concerns about its potential effects on the body. In a post shared on Instagram recently, he said, 'Can't do without bread every morning? Well… at least try to reduce. Because bread could be the most dangerous thing you put in your body.' His warning isn't just about processed ingredients or high-carb content — he points to a rare condition called auto-brewery syndrome, where the gut microbiome ferments carbohydrates, including those in bread, into ethanol. This can cause intoxication-like symptoms even without consuming alcohol. While this condition is uncommon, it raises important questions about how certain foods interact with gut health. Dr Mehta suggests a simple remedy for those who continue eating bread: 'Have Isabgol (Psyllium Husk) at night and first thing in the morning.' Auto-brewery syndrome is a rare condition where the body produces alcohol internally due to the fermentation of carbohydrates by an overgrowth of certain gut microbes, typically yeasts like Candida or specific bacteria. 'When the gut microbiome is disrupted — often after antibiotic use, a high-carbohydrate diet, or gastrointestinal disorders — fermentative organisms can proliferate,' explains Dr Adithya V. Naragund, senior consultant in GI & HPB Surgery at Cytecare Hospitals, Bengaluru. This imbalance leads to excessive ethanol production in the intestines, which gets absorbed into the bloodstream, causing symptoms of intoxication. 'Factors that increase the risk include a history of gut dysbiosis, diabetes, or other conditions that compromise the normal microbial balance, as well as diets high in refined carbohydrates,' mentions Dr Naragund. A post shared by Dr. Mickey Mehta (@mickey_mehta) For most people, moderate bread consumption — especially whole grain varieties — does not negatively impact gut health. However, excessive intake of refined bread, high in simple carbohydrates and low in fibre, can contribute to gut dysbiosis. 'This imbalance may promote the overgrowth of fermentative microorganisms, leading to bloating, gas, or low-grade inflammation,' says Dr Naragund. Those with metabolic or gastrointestinal issues may be more susceptible to adverse effects. On the other hand, fibre-rich breads can support gut health by nourishing beneficial bacteria and promoting digestion. Psyllium husk, a soluble fibre, plays a crucial role in digestive health. 'It works by absorbing water and forming a gel-like substance, which not only softens stool and aids in regular bowel movements but also helps modulate the fermentation process in the gut,' Dr Naragund explains. By slowing carbohydrate absorption, psyllium reduces rapid fermentation that can lead to excess gas or ethanol production, stabilising blood sugar levels and improving gut transit. To further support gut health, Dr Naragund suggests reducing processed carbohydrate intake, opting for whole grains, and maintaining a diet rich in fruits, vegetables, and lean proteins. 'Additionally, consuming probiotics — either through fermented foods or supplements – can replenish beneficial bacteria, while regular physical activity and stress management further contribute to overall gastrointestinal wellness.' DISCLAIMER: This article is based on information from the public domain and/or the experts we spoke to. Always consult your health practitioner before starting any routine.
Time of India
02-06-2025
- Health
- Time of India
Auto-Brewery Syndrome: The gut disorder that gets you drunk and mimics a hangover
Ever woken up feeling tipsy, dizzy, or foggy — without touching a single drop of alcohol? Sounds like a wild night you can't remember, right? But for some people, this bizarre feeling isn't the aftermath of a party. It's actually a rare condition called Auto-Brewery Syndrome (ABS) — and yes, it's as strange as it sounds. Imagine your gut turning into a mini brewery, fermenting food into alcohol and flooding your bloodstream with it. Sounds like science fiction? It's not. It's real, and it's throwing doctors — and patients — for a loop. What is Auto-Brewery Syndrome? Auto-Brewery Syndrome, also known as gut fermentation syndrome, is a rare medical condition where your digestive system starts producing ethanol (the same alcohol found in beer and wine) from the carbohydrates you eat. Instead of breaking down carbs the normal way, certain yeast or bacteria in your gut go rogue and start fermenting those sugars, turning your intestines into an unlicensed brewery. The result? You can actually get drunk without drinking alcohol. And we're not talking just a little lightheaded — some people with ABS have blown over the legal blood alcohol limit without ever having a drink. What causes it? The main culprits behind ABS are usually strains of yeast — most commonly Saccharomyces cerevisiae (aka baker's or brewer's yeast) and Candida species. These yeasts are normally harmless and even helpful in small amounts. But under certain conditions — like after a course of antibiotics that wipe out your good gut bacteria — yeast can overgrow and take over the gut environment. Once these microbes have free reign and access to carbs, they start fermenting food into alcohol right inside your body. It's like feeding sugar to yeast in a beer vat — but it's happening in your intestines. Who gets it? Auto-Brewery Syndrome is rare, but it doesn't discriminate. It's been found in both adults and children. However, it's more often seen in people who: Have had frequent antibiotic use (which can disrupt gut flora) Have gut imbalances or chronic conditions like Crohn's or diabetes Eat a high-carbohydrate diet Have weakened immune system The syndrome often goes undiagnosed or misdiagnosed for years. Many patients are mistaken for alcoholics or accused of drinking secretly because their blood alcohol levels are high — even when they swear they haven't touched a drop. Symptoms: It's not just 'feeling drunk' While the most headline-worthy symptom is spontaneous drunkenness, ABS comes with a laundry list of weird and confusing symptoms: Dizziness or disorientation Slurred speech Brain fog or confusion Fatigue Mood changes — including depression or irritability Bloating or gas (hello, fermentation!) Headaches or nausea Trouble concentrating People with ABS may experience symptoms at random, especially after meals rich in carbs or sugar. How is it diagnosed? Diagnosing Auto-Brewery Syndrome can be tricky — mostly because it's so rare and not on most doctors' radars. If you suspect it, the first step is tracking your symptoms and eating patterns. Blood and breath alcohol tests taken without alcohol consumption can show elevated levels of ethanol. Sometimes, a glucose challenge test is used. You basically eat a bunch of sugar and your blood alcohol is monitored afterward. If it spikes, bingo — you've got fermentation going on in your gut. Auto-Brewery Syndrome might sound quirky or even funny at first — 'drunk without drinking!' — but for people living with it, it's anything but amusing. It can affect relationships, jobs, mental health, and quality of life. Imagine trying to convince your doctor, boss, or even family that you're not secretly drinking when your blood alcohol level says otherwise. So next time someone says, 'I swear I didn't drink anything,' maybe… just maybe… they're telling the truth. Want to keep your gut in check and avoid unexpected fermentation? Eat balanced, limit unnecessary antibiotics, and take care of your microbiome. Because the last thing anyone wants is their belly turning into a brewery. One step to a healthier you—join Times Health+ Yoga and feel the change
Wales Online
31-05-2025
- Health
- Wales Online
Experts warn of 'growing concern' over fungus which is a 'threat to humanity'
Experts warn of 'growing concern' over fungus which is a 'threat to humanity' 'The reality is already scary enough', one expert has shared Candidozyma auris has been identified in the UK - but it's not widespread (Image: Getty ) Experts have issued a warning about a deadly fungus dubbed a "threat to humanity" which is now rapidly spreading. Originally discovered in Japan in 2009, Candidozyma (formerly known as Candida) auris (C. auris) has appeared in over 40 countries across six continents since it was identified in a patient's ear canal. It poses a significant threat according to the UK Health Security Agency (UKHSA) due to its extraordinary tenacity and ability to last for extensive periods on surfaces. The fungus's survival skills are not limited to persistence on surfaces: it often also shows resistance to everyday disinfectants and many antifungal medications. Infections can occur through various anatomical pathways, including invasion into the bloodstream, central nervous system (encompassing the brain and spinal cord), bones, abdominal cavity, wounds, ears, respiratory tract, or urinary system, reports the Mirror. Stay informed on the latest health news by signing up to our newsletter here People with existing medical conditions are at heightened danger, faced with potential mortality rates ranging from 30% to 60%, an alarming statistic highlighted by the Express. The UKHSA emphasised the public health issue, stating: "C. auris represents a growing global health concern, particularly in healthcare settings where it can spread rapidly and resist treatment and some disinfectants." "While not yet widespread in England, it is important that we remain aware that C. auris may spread in hospital environments. "Through effective infection prevention and control measures, rigorous hygiene practices, ongoing monitoring and continued research, its spread can be minimised. "C. auris primarily spreads through contact with contaminated surfaces or medical equipment, or via direct contact with individuals who are colonised. People can carry the fungus on their skin without developing an infection (called colonisation). However, someone who has C. auris on their skin may become infected if it enters their body, for example through a wound, or if they have had an invasive medical device inserted, for example a catheter or drip." The World Health Organisation (WHO) has spotlighted this fungus among 19 deadly fungi that represent a "serious threat to humanity", according to its recent report. The WHO highlighted how fungal infections "receive very little attention and resources, leading to a scarcity of quality data on fungal disease distribution and antifungal resistance patterns." Article continues below The organisation added: "As a result, the exact burden of fungal diseases and antifungal resistance, are unknown, and the response is therefore undermined." Dr Hanan Balkhy, WHO Assistant Director-General, Antimicrobial Resistance (AMR) said: "Emerging from the shadows of the bacterial antimicrobial resistance pandemic, fungal infections are growing, and are ever more resistant to treatments, becoming a public health concern worldwide."
Daily Mirror
30-05-2025
- Health
- Daily Mirror
Killer fungus warning as pathogen dubbed 'threat to humanity' spreading in UK
Candidozyma auris is 'particularly concerning' due to its 'remarkable resilience' which means it can survive on surfaces for a long time, said the UK Health Security Agency An urgent warning has been issued as a fungus described as a "threat to humanity" is now spreading across the UK. Candidozyma (formerly Candida) auris (C. auris) was first identified in the external ear canal of a patient in Japan in 2009, but has since been found in more than 40 countries across six continents. The UK Health Security Agency (UKHSA) said the fungus is "particularly concerning" because of its "remarkable resilience" which allows it to survive on surfaces for long periods of time. The yeast species is often resistant to disinfectants and common antifungal drugs too. A person can contract it through a fungal infection into the blood, brain and spinal cord, bones, abdomen, wounds, ears, respiratory tract, and urinary system. People who already have existing health issues are particularly at risk, as in extreme cases the fungus can be fatal in between 30% and 60% of patients, reports the Express. UKHSA said in a statement released yesterday: "C. auris represents a growing global health concern, particularly in healthcare settings where it can spread rapidly and resist treatment and some disinfectants. "While not yet widespread in England, it is important that we remain aware that C. auris may spread in hospital environments. Through effective infection prevention and control measures, rigorous hygiene practices, ongoing monitoring and continued research, its spread can be minimised. "C. auris primarily spreads through contact with contaminated surfaces or medical equipment, or via direct contact with individuals who are colonised. People can carry the fungus on their skin without developing an infection (called colonisation). However, someone who has C. auris on their skin may become infected if it enters their body, for example through a wound, or if they have had an invasive medical device inserted, for example a catheter or drip." The World Health Organisation (WHO) has listed the fungus among 19 lethal fungi that pose a "serious threat to humanity" in a recent report. The health organisation said fungal infections "receive very little attention and resources, leading to a scarcity of quality data on fungal disease distribution and antifungal resistance patterns." It added: "As a result, the exact burden of fungal diseases and antifungal resistance, are unknown, and the response is therefore undermined." Dr Hanan Balkhy, WHO Assistant Director-General, Antimicrobial Resistance (AMR), said: "Emerging from the shadows of the bacterial antimicrobial resistance pandemic, fungal infections are growing, and are ever more resistant to treatments, becoming a public health concern worldwide." Earlier this month, a new climate change study warned that a deadly fungus that already infects millions of people in warmer parts of the world could soon spread across Europe and reach the UK. The Aspergillus fungus - already a known threat in tropical and subtropical climates - causes serious brain infections in humans, kills livestock, and renders crops unsafe to eat. Now, with global temperatures rising, researchers say its reach is expanding rapidly, and the UK could be next. Viewers of The Last of Us might recognise the fictional version of this threat, but "the reality is already scary enough," said lead author Dr Norman van Rhijn from the University of Manchester, speaking to Sky News. Dr van Rhijn warned that infections like invasive aspergillosis - which spreads from the lungs to other organs - currently kill 1.8million people globally each year. 'Most fungi live in the environment,' he said. 'Because that environment is rapidly changing, we will definitely see different kinds of diseases and infections popping up over the next 50 years or so.' The new research shows that species such as Aspergillus fumigatus, flavus, and niger are set to move northward from their current hotspots in Africa and South America, reaching parts of Europe, the UK, and even Scandinavia. In an optimistic climate scenario where warming is limited to around 2C, Aspergillus fungi would still expand significantly - while likely retreating from southern Europe, which may become too hot even for these heat-loving pathogens.
Yahoo
29-05-2025
- Business
- Yahoo
ExThera Medical's Blood Filtration Device Shows Promise for Sepsis Patients After Cardiac Surgery
New Study Shows Seraph 100 Removes Pathogens, Improves Outcomes MARTINEZ, Calif., May 29, 2025--(BUSINESS WIRE)--A newly published study in Nature's Scientific Reports finds that use of ExThera's Seraph® 100 blood filter in septic patients following cardiac surgery significantly improved outcomes by rapidly reducing pathogen load in the bloodstream. Sepsis—a life-threatening condition caused by the body's extreme response to infection—can lead to organ failure and death if not treated quickly. Patients undergoing surgery for infective endocarditis (IE), a serious infection of the heart's inner lining, face particularly high risk of developing post-operative sepsis due to widespread bacterial contamination in the blood. The hospital-led study, conducted at the ICU of Papardo Hospital in Messina, Italy, evaluated patients who developed sepsis after cardiac surgery for IE. Thirteen patients were treated with the Seraph® 100 Microbind® Affinity Blood Filter (Seraph 100), and their outcomes were compared to a retrospective control group of fifteen patients who did not receive the treatment. Within just four hours of using the Seraph 100 filter, pathogen load in the bloodstream dropped significantly. In addition to fighting the infection, patients who received this treatment also showed signs of faster recovery, including: Lower levels of inflammation in the body based on various biomarkers More stable blood pressure Reduced need for medications that support blood pressure Shorter stays in the ICU Importantly, only 15% of patients who received the Seraph 100 developed acute kidney injury (AKI) that required dialysis—a common and serious complication of sepsis—compared to 40% in the untreated group. Impressively, in this study, two dangerous and difficult-to-treat pathogens – Pseudomonas and Candida – were effectively removed. Candida organisms have been identified as "superbugs" with few treatment options. These data suggest that the Seraph 100 may have utility for these difficult-to-treat infections. "These results suggest the Seraph 100 device can help critically ill patients recover more quickly by removing harmful and difficult-to-treat pathogens like Staph, Pseudomonas, and Candida species," said Mink Chawla, MD, Chief Medical Officer of ExThera. "The authors document improved clinical outcomes with the use of Seraph 100 technology and also demonstrated the ability for the filter to capture intact pathogens thereby allowing the Seraph 100 to be an effective diagnostic tool for blood-borne pathogens." The results of the study were published in Nature's Scientific Reports. About ExThera Medical Corporation ExThera Medical Corporation develops extracorporeal blood filtration devices, including the Seraph® 100 Microbind® Affinity Blood Filter (Seraph 100) for removing a broad range of pathogens from the bloodstream of patients. Seraph 100 can be used in hospitals, clinics, on battlefields and in other austere environments to address nosocomial and community-acquired infections as well as those caused by battlefield wounds, pandemics, and biological warfare agents. ExThera Medical's extracorporeal products have demonstrated life-saving capabilities in a wide range of critically ill patients suffering from sepsis, COVID-19, and many other severe bloodstream infections. With a growing body of outcome and health economic evidence from independent clinical studies, success in the DARPA Dialysis-Like Therapeutics program, and from successful clinical use in the U.S., the EU, and the Middle East, the company is well positioned to serve healthcare professionals and patients alike. The Seraph 100 device has neither been cleared nor approved by the U.S. Food and Drug Administration (FDA) for any indication. The Seraph 100 has been authorized by FDA under an Emergency Use Authorization (EUA) to treat patients with COVID-19 infection. The Seraph 100 is authorized only for the duration of the declaration that circumstances exist justifying the authorization of the emergency use of the Seraph 100 device under section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner. For more information, visit the company's website at About Seraph 100 and the ONCObind Procedure As a patient's blood flows through the Seraph® 100 Microbind® Affinity Filter (Seraph 100), it passes through a bed of small beads with receptors that mimic the receptors on human cells that pathogens target when they invade the body. Many harmful substances are quickly captured and adsorbed onto the surface of the beads and are thereby subtracted from the bloodstream. Seraph 100 adds nothing to the bloodstream. It targets the pathogens that cause the infection, while it also binds and removes harmful substances generated by the pathogen and by the body's response to the infection. Seraph's proprietary adsorption media (the beads) constitute a flexible platform that uses immobilized (chemically bonded) heparin for its well-established blood compatibility and its unique ability to bind circulating tumor cells, bacteria, viruses, fungi, and important sepsis mediators reported to contribute to organ failure during sepsis. ExThera Medical is currently developing the ONCObind Procedure Hemoperfusion Filter (ONCObind) to support cancer treatment. ONCObind is part of the same platform technology as Seraph 100. For more news stories on Seraph 100 and ONCObind, click here. Disclaimer All information contained in this news release derives from plausible, reliable sources, however they have not been independently examined or verified. There is no representation, warranty, or guarantee provided herein. Except as otherwise required by appliable law, all liability for any direct or indirect claims, damages or losses are hereby disclaimed whether or not foreseeable. This communication includes forward-looking statements regarding events, trends and business prospects that may affect our future operating results and financial position. Such statements are subject to risks and uncertainties that could cause our actual results and financial position to differ materially. Accordingly, the investment and/or the revenues that arise from it can rise or fall or fail entirely. We assume no responsibility to update or revise any statements contained in this news release, including forward-looking, to reflect events, trends, or circumstances that might arise after the date of this news release. Results from case studies (reviews) may not be predictive of future results. View source version on Contacts Stephanie Connollymedia@
